Neal Muni - May 19, 2022 Form 3/A - Amendment Insider Report for Comera Life Sciences Holdings, Inc. (CMRA)

Role
Executive Vice President and Chief Operating Officer. Exhibit 24 Power of Attorney filed herewith.
Signature
/s/ Ryan M. Rourke Reed, Attorney-in-Fact
Stock symbol
CMRA
Transactions as of
May 19, 2022
Transactions value $
$0
Form type
3/A - Amendment
Date filed
2/14/2023, 04:15 PM
Date Of Original Report
May 20, 2022
Next filing
Aug 11, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding CMRA Stock Option (Right to Buy) May 19, 2022 Common Stock 208K $0.59 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This Form 3/A is being filed to correct information previously disclosed on the original Form 3 filed by the reporting person on May 20, 2022, including the Exercise Price, Amount or Number of Shares and vesting schedule of the stock option grant. This Form 3/A also includes the reporting person's power-of-attorney.
F2 This option was issued pursuant to the terms of a business combination agreement involving the issuer and Comera Life Sciences, Inc. in exchange for a comparable option previously issued by such company on September 16, 2021. 25% of the option vests or vested on the one year anniversary of the grant date and in equal monthly installments thereafter for 36 months.

Remarks:

Executive Vice President and Chief Operating Officer. Exhibit 24 Power of Attorney filed herewith.